Proactive Investors - Run By Investors For Investors

Imugene to make further cancer vaccine research presentations at AACR annual meeting

The AACR annual meeting will be held in Atlanta Georgia, between March 29 and April 3.
Imugene to make further cancer vaccine research presentations at AACR annual meeting
Imugene is a clinical stage immune-oncology company

Imugene Ltd (ASX:IMU) will present on its KEY-Vaxx an B-Vaxx cancer vaccine programs at the American Association for Cancer Research’s (AACR) 2019 annual meeting.

The presentations will be made by Dr Tanios Bekaii-Saab from the Mayo Clinic, the co-inventor of the KEY-Vaxx and B-Vaxx cancer vaccines along with Imugene scientific advisor Professor Pravin Kaumaya.

Content from the presentations remains embargoed until the start of the conference and will be made available online after the annual meeting begins.


The first abstract presentation is entitled ‘Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumour growth in a syngeneic Balc/c model challenged with CT26/HER-2 carcinoma cell line’.

The second is called ‘A phase-one active immunotherapy with a combination of two Chimeric (Trastuzumab-like and Pertuzumab-like) human epiderman growth factor receptor 2 (HER-2) B cell peptide vaccine emulsified in ISA 720 and Nor-MDP adjuvant in patients with advanced solid tumours

READ: Imugene to present cancer vaccine research at AACR annual meeting

Imugene’s KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction.

It is also designed to produce an anti-cancer effect similar to Keytrude, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming cancer treatment.

KEY-Vaxx when combined with B-Vaxx has shown great potential in pre-clinical studies, demonstrating robust PD-1 and HER-2 antibody responses in all vaccinated mice.

This indicates that the combined vaccination is effective in reducing tumour growth in a Balc/c syngeneic model of colon carcinoma versus either the PD-1 vaccine alone or more important the positive control gold standard that is anti-mouse PD-1 monoclonal antibody.

The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity.

READ: Imugene has cancer vaccine trial data published in prestigious medical journal

B-Vaxx is a proprietary B-cell peptide cancer vaccine being developed that targets multiple oncology indications.

The phase-one B-Vaxx trial studied the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumours.

The open-label, dose escalation study evaluated B-Vaxx in patients with solid tumours that over-express the HER-2/neu receptor.

B-Vaxx has been shown to stimulate a potent polyclonal antibody response to HER-2/nue, a well-established and validated cancer target.

A phase-two study evaluating the activity of B-Vaxx in patient over-expressing HER-2/nue is being conducted at clinical institutions in the US.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

February 22 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
young girl with allergy
April 29 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use